Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83aafb03d05a4f159e72936107a43a7e
record_format	dspace
spelling	oai:doaj.org-article:83aafb03d05a4f159e72936107a43a7e2021-12-02T17:08:35ZNovel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab10.1038/s41598-021-96538-72045-2322https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96538-7https://doaj.org/toc/2045-2322Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2%. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival. The score, generated by combining these factors, was associated with survival. Patients with score of 4–5 had worse survival than those with score of 2–3 and 0–1 [adjusted HR for PFS: score of 4–5, 7.77 (3.98–15.15); score of 2–3, 3.44 (1.95–6.06), compared to score of 0–1], [adjusted HR for OS: score of 4–5, 14.66 (4.28–50.22); score of 2–3, 7.63 (2.29–25.37), compared to score of 0–1]. Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in RM-HNC patients treated with nivolumab therapy.Kiyoshi MinoharaTakuma MatobaDaisuke KawakitaGaku TakanoKeisuke OguriAkihiro MurashimaKazuhiro NakaiSho IwakiWataru HojoAyano MatsumuraShinya OzakiTaijiro OzawaIkuma HarataNobukazu TanakaShinichiro MasekiHiroshi TsugeSae ImaizumiShoji MitsuyaKazuho MoribeShinichi EsakiShinichi IwasakiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kiyoshi Minohara Takuma Matoba Daisuke Kawakita Gaku Takano Keisuke Oguri Akihiro Murashima Kazuhiro Nakai Sho Iwaki Wataru Hojo Ayano Matsumura Shinya Ozaki Taijiro Ozawa Ikuma Harata Nobukazu Tanaka Shinichiro Maseki Hiroshi Tsuge Sae Imaizumi Shoji Mitsuya Kazuho Moribe Shinichi Esaki Shinichi Iwasaki Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
description	Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2%. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival. The score, generated by combining these factors, was associated with survival. Patients with score of 4–5 had worse survival than those with score of 2–3 and 0–1 [adjusted HR for PFS: score of 4–5, 7.77 (3.98–15.15); score of 2–3, 3.44 (1.95–6.06), compared to score of 0–1], [adjusted HR for OS: score of 4–5, 14.66 (4.28–50.22); score of 2–3, 7.63 (2.29–25.37), compared to score of 0–1]. Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in RM-HNC patients treated with nivolumab therapy.
format	article
author	Kiyoshi Minohara Takuma Matoba Daisuke Kawakita Gaku Takano Keisuke Oguri Akihiro Murashima Kazuhiro Nakai Sho Iwaki Wataru Hojo Ayano Matsumura Shinya Ozaki Taijiro Ozawa Ikuma Harata Nobukazu Tanaka Shinichiro Maseki Hiroshi Tsuge Sae Imaizumi Shoji Mitsuya Kazuho Moribe Shinichi Esaki Shinichi Iwasaki
author_facet	Kiyoshi Minohara Takuma Matoba Daisuke Kawakita Gaku Takano Keisuke Oguri Akihiro Murashima Kazuhiro Nakai Sho Iwaki Wataru Hojo Ayano Matsumura Shinya Ozaki Taijiro Ozawa Ikuma Harata Nobukazu Tanaka Shinichiro Maseki Hiroshi Tsuge Sae Imaizumi Shoji Mitsuya Kazuho Moribe Shinichi Esaki Shinichi Iwasaki
author_sort	Kiyoshi Minohara
title	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
title_short	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
title_full	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
title_fullStr	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
title_full_unstemmed	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
title_sort	novel prognostic score for recurrent or metastatic head and neck cancer patients treated with nivolumab
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e
work_keys_str_mv	AT kiyoshiminohara novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT takumamatoba novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT daisukekawakita novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT gakutakano novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT keisukeoguri novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT akihiromurashima novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT kazuhironakai novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shoiwaki novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT wataruhojo novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT ayanomatsumura novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shinyaozaki novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT taijiroozawa novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT ikumaharata novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT nobukazutanaka novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shinichiromaseki novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT hiroshitsuge novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT saeimaizumi novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shojimitsuya novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT kazuhomoribe novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shinichiesaki novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab AT shinichiiwasaki novelprognosticscoreforrecurrentormetastaticheadandneckcancerpatientstreatedwithnivolumab
_version_	1718381563533590528

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

Ejemplares similares